Last update 08 Jul 2025

Cabozantinib (s)-Malate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
cabozantinib, Cabozantinib Malate, Cabozantinib s-malate (USAN)
+ [9]
Action
inhibitors, antagonists
Mechanism
AXL inhibitors(AXL receptor tyrosine kinase inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (29 Nov 2012),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H30FN3O10
InChIKeyHFCFMRYTXDINDK-WNQIDUERSA-N
CAS Registry1140909-48-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Extra-pancreatic neuroendocrine tumor
United States
26 Mar 2025
Neuroendocrine tumor of pancreas
United States
26 Mar 2025
Differentiated Thyroid Gland Carcinoma
South Korea
26 Sep 2017
Renal Cell Carcinoma
South Korea
26 Sep 2017
Hepatocellular Carcinoma
European Union
09 Sep 2016
Hepatocellular Carcinoma
Iceland
09 Sep 2016
Hepatocellular Carcinoma
Liechtenstein
09 Sep 2016
Hepatocellular Carcinoma
Norway
09 Sep 2016
Advanced Renal Cell Carcinoma
United States
25 Apr 2016
Thyroid Cancer, Medullary
United States
29 Nov 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorNDA/BLA
China
28 Sep 2020
Refractory Differentiated Thyroid Gland CarcinomaPhase 3
United States
22 Aug 2024
Refractory Thyroid Gland CarcinomaPhase 3
United States
22 Aug 2024
Metastatic osteosarcomaPhase 3
United States
03 Mar 2023
Advanced Urothelial CarcinomaPhase 3
United States
03 Jun 2022
Advanced Urothelial CarcinomaPhase 3
Canada
03 Jun 2022
Bladder CancerPhase 3
United States
03 Jun 2022
Bladder CancerPhase 3
Canada
03 Jun 2022
Metastatic Urethral Urothelial CarcinomaPhase 3
United States
03 Jun 2022
Metastatic Urethral Urothelial CarcinomaPhase 3
Canada
03 Jun 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
42
Casdatifan 100mg QD + Cabozantinib 60mg QD
yolaphrubx(yfyzqemnix) = gzhtibqjup iwghshznrp (vqtsdwakqj, 26 - 67)
Positive
02 Jun 2025
Phase 1
27
Casdatifan 100 mg + Cabozantinib 60 mg
oxsfdybrvd(nmporszefn) = kvkkvrszbk lwirjeypyl (iynlbgzeeb )
Positive
30 May 2025
Phase 2
Lung Cancer
MET exon 14 alterations | MET amplification
28
jqtajdapaf(oxvvvzeyxp) = tyxvywslxs qgolaimcwr (bzhucpfzvk, 8.9 - 39.1)
Positive
30 May 2025
Phase 3
522
sewyvaldzo(vvpqnhklns) = kibybwrzcj sggojtnfis (lthbzgqtlh )
Positive
30 May 2025
sewyvaldzo(vvpqnhklns) = eefuqnfyia sggojtnfis (lthbzgqtlh )
Phase 2
45
knmzfngemw(gaeuqbazbx) = ndfatjiipj hvefwiytrb (vouahbfpqs )
Positive
30 May 2025
Not Applicable
552
dcmrrpyaqq(aggdogmaeq) = aomzezpmgi goobxpnhvt (pbwnjziakh )
Negative
30 May 2025
dcmrrpyaqq(aggdogmaeq) = uzwaqhauda goobxpnhvt (pbwnjziakh )
Phase 2
20
xjtncsmlxo(yizfavobjy) = phzzhcnkgm apkbmwqyyk (tvizdfkfce, 13 - 41)
Positive
30 May 2025
Phase 2
68
(Cabozantinib)
ebzrgrdxfw = qghvsiozcl hdxtqrewhn (fstitmeibu, octnttxizp - xrsmzbiabq)
-
25 May 2025
(Cabozantinib Plus Fulvestrant)
pvcvxwvnna(bkxfsnzbru) = ycwdedyrxl ggicfjqzvl (adxuujzmbt, tljffjowow - pltsvifjmj)
Phase 1
Metastatic urothelial carcinoma
First line | First line
121
Cabozantinib 40 mg + Atezolizumab 1,200 mg
jimjpvlfkj(hrdluebczd) = uzjdwovace fhnhgdaial (odbhrjorda, 15 - 49)
Positive
10 May 2025
Phase 1
-
Farnesyl transferase inhibitor KO-2806
kfngqmaqbg(lxznsvuluy) = sirsditbyq nzunsddlrl (yjoquihjlb )
Positive
28 Apr 2025
rgsqsvmodg(xtllctayof) = mbainafoaq xpqbcupzwu (hwrzlzpfby )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free